Skip to main content

Newsroom press releases

01/12/22 - 18:30

2023 Annual Calendar of Corporate Events (288 KB)
Other
Download

09/11/22 - 7:04

DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
Products Molecular
Download

07/11/22 - 7:12

DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
Products Molecular
Download

27/10/22 - 13:44

Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
Financial Data
Download

05/10/22 - 6:37

DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
Products Molecular
Download

14/09/22 - 0:29

DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
Products Molecular
Download

03/08/22 - 12:26

Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
Financial Data
Download

14/07/22 - 20:00

DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
Products Immunodiagnostic
Download

07/06/22 - 18:06

Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
Other
Download

20/05/22 - 7:08

DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
Products Molecular
Download

09/05/22 - 7:02

DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
Acquisition / Partnership
Download

06/05/22 - 17:33

Update 2022 Annual Calendar of Corporate Events (285.68 KB)
Financial Disclosures
Download

06/05/22 - 16:45

Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
Financial Data
Download

02/05/22 - 12:55

Publication of the summary report of the votes cast (280.95 KB)
Financial Disclosures
Download

29/04/22 - 16:26

Shareholders' meeting 2022 (166.12 KB)
Other
Download

22/04/22 - 12:37

New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
Financial Disclosures
Download

13/04/22 - 16:43

DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
Financial Disclosures
Download

08/04/22 - 19:13

Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
Financial Disclosures
Download

08/04/22 - 9:53

Update annual calendar of corporate events 2022 (288.09 KB)
Financial Disclosures
Download

05/04/22 - 9:51

Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
Other
Download

04/04/22 - 18:12

Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
Other
Download

16/03/22 - 17:39

DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
Financial Data
Download

08/03/22 - 7:13

DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
Products Molecular
Download

13/01/22 - 7:24

DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
Products Molecular
Download

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
Products Molecular
Download

29/11/17 - 19:30

Resignation of a Strategic Executive of the Company (233.58 KB)
Other
Download

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
Financial Data
Download

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
Financial Data
Download

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
Acquisition / Partnership
Download

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
Products Molecular
Download

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
Financial Data
Download

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
Products Molecular
Download

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
Acquisition / Partnership
Download

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
Products Molecular
Download

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
Financial Data
Download

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
Acquisition / Partnership
Download

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
Acquisition / Partnership
Download

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
Products Immunodiagnostic
Download

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
Products Immunodiagnostic
Download

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
Financial Data
Download

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)
Financial Data
Download

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
Products Immunodiagnostic
Download

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
Products Immunodiagnostic
Download

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)
Financial Data
Download

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
Products Molecular
Download

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
Products Immunodiagnostic
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.